A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa
NCT06628947
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
36
Enrollment
INDUSTRY
Sponsor class
Conditions
Retinitis Pigmentosa
Interventions
OTHER:
Placebo (Sterile Saline or Balanced Salt Solution)
DRUG:
100 μg KIO-301
DRUG:
50 μg KIO-301
Sponsor
Kiora Pharmaceuticals, Inc.